Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease

A method of treating or ameliorating levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, said method comprising administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of formula (I):

• wherein in formula (I):
• R1, R2 and R3 are independently selected from the group consisting of H, cyano, hydroxyl, amino, acetamido, halo, alkoxy, nitro, C1-6 alkyl, substituted C1-6 alkyl, heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, aryl-(C1-3)alkyl, substituted aryl-(C1-3)alkyl, carboxy, alkylcarboxy, formyl, alkyl-carbonyl, aryl-carbonyl, and heteroaryl-carbonyl;
• R4 and R5 are independently selected from the group consisting of H, C1-6 alkyl, substituted C1-6 alkyl, heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, aryl-(C1-3)alkyl, and substituted aryl-(C1-3)alkyl;
• and,
• n is 2, 3, 4 or 5
• R mixtures thereof, or a pharmaceutically acceptable salt thereof.

A method of treating or ameliorating Parkinson's Disease in a patient, said method comprising administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of at least one compound:

• of formula (I):
• wherein in formula (I):
• R1, R2 and R3 are independently selected from the group consisting of H, cyano, hydroxyl, amino, acetamido, halo, alkoxy, nitro, C1-6 alkyl, substituted C1-6 alkyl, heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, aryl-(C1-3)alkyl, substituted aryl-(C1-3)alkyl, carboxy, alkylcarboxy, formyl, alkyl-carbonyl, aryl-carbonyl, and heteroaryl-carbonyl;
• R4 and R5 are independently selected from the group consisting of H, C1-6 alkyl, substituted C1-6 alkyl, heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, aryl-(C1-3)alkyl, and substituted aryl-(C1-3)alkyl;
• and,
• n is 2, 3, 4 or 5
• mixtures thereof, or a pharmaceutically acceptable salt thereof.

A method of treating or ameliorating levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, said method comprising administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of at least one compound selected from the group consisting of:

• 2-amino-4-(2-chlorophenyl)butan-1-ol;
• 2-(3-aminohexyl)phenol;
• 4-(2-chlorophenyl)-2-methylamino-butane;
• 4-(2-fluorophenyl)butan-2-amine;
• 4-(2-bromophenyl)butan-2-amine;
• 4-(2-iodophenyl)butan-2-amine;
• 4-(2-methoxyphenyl)butan-2-amine;
• 2-(3-aminobutyl)phenol;
• 3-(3,4-diethoxyphenyl)propan-1-amine;
• 4-(4-chlorophenyl)butan-2-amine;
• 4-(4-methoxyphenyl)butan-2-amine;
• mixtures thereof, or a pharmaceutically acceptable salt thereof.

A method of treating or ameliorating Parkinson's Disease in a patient, said method comprising administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of at least one compound selected from the group consisting of:

• 2-amino-4-(2-chlorophenyl)butan-1-ol;
• 2-(3-aminohexyl)phenol;
• 4-(2-chlorophenyl)-2-methylamino-butane;
• 4-(2-fluorophenyl)butan-2-amine;
• 4-(2-bromophenyl)butan-2-amine;
• 4-(2-iodophenyl)butan-2-amine;
• 4-(2-methoxyphenyl)butan-2-amine;
• 2-(3-aminobutyl)phenol;
• 3-(3,4-diethoxyphenyl)propan-1-amine;
• 4-(4-chlorophenyl)butan-2-amine;
• 4-(4-methoxyphenyl)butan-2-amine;
• mixtures thereof, or a pharmaceutically acceptable salt thereof.